Sertoli Cell Microencapsulation for Type 1 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Type 1 diabetes mellitus, such as insulin administration and islet transplantation, fail to replicate the natural pulsatile insulin secretion and are hindered by limited donor availability, immunosuppressive side effects, and poor islet survival, necessitating a more effective approach to restore pancreatic function.
Innovation Solution
Microencapsulation of Sertoli cells in hydrogel-based microspheres, which induces beta-cell neogenesis and modulates the autoimmune response, preventing and treating Type 1 diabetes without the need for islet transplantation, using a process that produces homogeneous microcapsules of smaller size without tail structures, maintaining cell vitality and functionality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If islet transplantation is performed to restore pancreatic function, then beta-cell replacement is achieved, but immunosuppressive side effects and rejection occur
Solution Approach 1:
An immunoprotective device comprising a biocompatible capsule containing Sertoli cells is introduced as an intermediary between the host immune system and the beta-cell replacement function. The capsule acts as a physical barrier that prevents immune cell infiltration while allowing metabolic exchange, thereby protecting the transplanted cells from autoimmune attack without requiring systemic immunosuppression
Solution Approach 2:
The immunoprotective device provides localized immune protection at the transplantation site through the biocompatible capsule structure. The capsule creates a localized immunoprivileged microenvironment that selectively blocks immune cells while permitting nutrient and waste exchange, addressing the immune rejection problem locally rather than systemically
2Reliability
If hexogen insulin therapy is used to restore glucide homeostasis, then blood sugar control is achieved, but the natural pulsatile insulin secretion rhythm is not replicated
Solution Approach 1:
The Sertoli cells within the immunoprotective device are capable of self-regulated insulin production and secretion in response to physiological stimuli. The encapsulated cells maintain their native functionality and respond dynamically to blood glucose levels, automatically adjusting insulin release patterns without external intervention or mechanical regulation
Solution Approach 2:
The transplanted Sertoli cells exhibit dynamic parameter changes in their insulin secretion behavior, transitioning from a static hormone replacement approach to a dynamic, stimulus-responsive system. The cells modulate their secretion rate, timing, and amplitude in response to varying glucose concentrations, recreating the physiological pulsatile pattern
3Reliability
If conventional microencapsulation is used to protect transplanted cells, then immune protection is provided, but microcapsule heterogeneity and tail structures reduce effectiveness
Solution Approach 1:
The microencapsulation process parameters are optimized to produce microcapsules with controlled size distribution (300-700 μm diameter) and uniform spherical morphology. By adjusting extrusion pressure, gelation conditions, and crosslinking parameters, the process eliminates tail formations and achieves homogeneous microcapsule populations with consistent immunoprotective properties
Solution Approach 2:
The conventional multi-step microencapsulation process is replaced by a streamlined extrusion-gelation-crosslinking sequence that directly produces homogeneous microcapsules. The method substitutes complex assembly operations with a controlled fluid dynamics approach where suspension extrusion through calibrated orifices followed by instantaneous gelation yields uniform spherical structures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microencapsulated Sertoli cells effectively prevent and treat Type 1 diabetes by reducing autoimmune destruction of beta-cells, normalizing glycemia, and reeducating the immune system, as demonstrated in animal models, with improved microcapsule features and increased cell functionality.
Implementation Method 1
introduced in a needle-type element to be divided into highly homogeneous microdroplets by means of a jet, advantageously an air jet
Implementation Method 2
The microdroplets are then gelified in an aqueous solution containing divalent cations
Implementation Method 3
Microencapsulation of Sertoli cells in hydrogel-based microspheres
Data Source
AI summary
The invention relates to the use of Sertoli cells (SC) microencapsulated into hydrogel-based microcapsules, for the prevention and/or treatment of Type 1 diabetes mellitus (T1DM) and to a process for producing microcapsules, preferably shaped as microspheres.